Phase III Regorafenib trial meets primary endpoint

/Phase III Regorafenib trial meets primary endpoint

Phase III Regorafenib trial meets primary endpoint

By |2014-09-17T09:23:52+00:00June 1st, 2012|News, Stivarga|

Bayer recently announced the results of its Phase III trial for regorafenib (BAY 73-4506), which is designed for patients with metastatic and/or unresectable GIST that have failed both imatinib and sunitinib.

Results from the trial showed a statistically significant improvement in progression-free survival, and the safety and tolerability of regorafenib were consistent with what had been seen in earlier studies.

Data from this study will be presented at an upcoming scientific meeting, and Bayer has plans to file for U.S. approval of regorafenib for the treatment of metastatic GIST.

This is of course a potentially exciting development as effective third-line drugs are sorely needed, and we will be sure to report any further information as soon as it becomes available.

Recent Posts

Upcoming Events

  1. GDOL Los Angeles 2019

    February 16 @ 8:00 AM - 5:00 PM
  2. GIST Laugh

    March 8 @ 7:00 PM - 10:00 PM
  3. GIST DO IT NJ

    May 4 @ 8:00 AM - 11:00 AM